Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01919229
- Locations
- 🇺🇸
University of California at Los Angeles UCLA SC, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital SC-9, Boston, Massachusetts, United States
🇺🇸University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8), Houston, Texas, United States
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Institut fuer Frauengesundheit
- Target Recruit Count
- 3545
- Registration Number
- NCT01908556
- Locations
- 🇩🇪
Frauenklinik University Hospital, Erlangen, Bavaria, Germany
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 256
- Registration Number
- NCT01872260
- Locations
- 🇺🇸
Univ of California at San Diego Moores Cancer Ctr, San Diego, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01870505
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT01814449
- Locations
- 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01814397
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT01797718
- Locations
- 🇫🇮
Kotka Central Hospital, Kotka, Finland
🇫🇮Kuopio University Central Hospital, Kuopio, Finland
🇫🇮Helsinki University Central Hospital, Helsinki, Finland
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01797523
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial City Medical Center, Houston, Texas, United States
🇺🇸MD Anderson Cooper Cancer Center, Voorhees, New Jersey, United States
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT01791478
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2020-03-04
- Target Recruit Count
- 412
- Registration Number
- NCT01758146
- Locations
- 🇮🇳
Department of Radiotherapy, Post Graduate Institute of Medical Education & Research, Chandigarh, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.